Editas

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company based in Cambridge, MA. Specializing in the development and commercialization of innovative therapies for rare diseases, the company focuses on addressing unmet medical needs in niche patient populations. With a commitment to research and development, Aegerion Pharmaceuticals, Inc strives to improve the lives of individuals living with rare diseases through the advancement of novel treatment options. By collaborating with healthcare professionals and patients, the company aims to make a meaningful impact in the field of rare disease management. Generated from their business information

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website

Paratek Pharmaceuticals, based in Boston, MA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). With a focus on developing innovative treatment options for complex medical issues, Paratek is committed to combatting AMR through responsible antibiotic use, improved surveillance, and research into new antibiotics. Grounded in a mission to save lives, Paratek's FDA-approved tetracycline-class antibiotic, NUZYRA, targets adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company's disciplined team of experts is driven to provide new technologies that can defeat superbugs and contribute to a vibrant marketplace that recognizes the life-saving value of novel antibiotics.Generated from the website